Your browser doesn't support javascript.
loading
Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.
Klumpp, Klaus; Shimada, Takashi; Allweiss, Lena; Volz, Tassilo; Lütgehetmann, Marc; Hartman, George; Flores, Osvaldo A; Lam, Angela M; Dandri, Maura.
Afiliación
  • Klumpp K; Novira Therapeutics Inc, part of the Janssen Pharmaceutical Companies, Doylestown, Pennsylvania. Electronic address: klausgklumpp@gmail.com.
  • Shimada T; PhoenixBio Co., Ltd., Higashi-Hiroshima, Japan.
  • Allweiss L; I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Volz T; I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Lütgehetmann M; I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Institute of Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Hartman G; Novira Therapeutics Inc, part of the Janssen Pharmaceutical Companies, Doylestown, Pennsylvania.
  • Flores OA; Novira Therapeutics Inc, part of the Janssen Pharmaceutical Companies, Doylestown, Pennsylvania.
  • Lam AM; Novira Therapeutics Inc, part of the Janssen Pharmaceutical Companies, Doylestown, Pennsylvania.
  • Dandri M; I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Infection Research, Hamburg-Lübeck-Borstel Partner Site, Germany.
Gastroenterology ; 154(3): 652-662.e8, 2018 02.
Article en En | MEDLINE | ID: mdl-29079518
ABSTRACT
BACKGROUND &

AIMS:

NVR3-778 is a capsid assembly modulator in clinical development. We determined the in vivo antiviral efficacy and effects on innate and endoplasmic reticulum (ER) stress responses of NVR3-778 alone or in combination with pegylated interferon alpha (peg-IFN) and compared with entecavir.

METHODS:

We performed 2 studies, with a total of 61 uPA/SCID mice with humanized livers. Mice were infected with a hepatitis B virus (HBV) genotype C preparation; we waited 8 weeks for persistent infection of the human hepatocytes in livers of mice. Mice were then randomly assigned to groups (5 or 6 per group) given vehicle (control), NVR3-778, entecavir, peg-IFN, NVR3-778 + entecavir, or NVR3-778 + peg-IFN for 6 weeks. We measured levels of HB surface antigen, HB e antigen, HBV RNA, alanine aminotransferase, and human serum albumin at different time points. Livers were collected and analyzed by immunohistochemistry; levels of HBV DNA, covalently closed circular DNA, and HBV RNA, along with markers of ER stress and IFN response, were quantified.

RESULTS:

Mice given NVR3-778 or entecavir alone for 6 weeks had reduced serum levels of HBV DNA compared with controls or mice given peg-IFN. The largest reduction was observed in mice given NVR3-778 + peg-IFN; in all mice in this group, the serum level of HBV DNA was below the limit of quantification. NVR3-778 and peg-IFN, but not entecavir, also reduced serum level of HBV RNA. The largest effect was obtained in the NVR3-778 + peg-IFN group, in which serum level of HBV RNA was below the limit of quantification. Levels of HB surface antigen and HB e antigen were reduced significantly in only the groups that received peg-IFN. Levels of covalently closed circular DNA did not differ significantly among groups. NVR3-778 was not associated with any significant changes in level of alanine aminotransferase, the ER stress response, or IFN-stimulated genes.

CONCLUSIONS:

NVR3-778 has high antiviral activity in mice with humanized livers and stable HBV infection, reducing levels of serum HBV DNA and HBV RNA. Entecavir reduced levels of serum HBV DNA, but had no effect on HBV RNA. The combination of NVR3-778 and peg-IFN prevented viral replication and HBV RNA particle production to a greater extent than each compound alone or entecavir.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antivirales / Polietilenglicoles / Activador de Plasminógeno de Tipo Uroquinasa / Virus de la Hepatitis B / Interferón-alfa / Hepatocitos / Guanina / Hepatitis B Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Gastroenterology Año: 2018 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antivirales / Polietilenglicoles / Activador de Plasminógeno de Tipo Uroquinasa / Virus de la Hepatitis B / Interferón-alfa / Hepatocitos / Guanina / Hepatitis B Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Gastroenterology Año: 2018 Tipo del documento: Article